Michael Santosuosso
Overview
Explore the profile of Michael Santosuosso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Santosuosso M, McCormick S, Roediger E, Zhang X, Zganiacz A, Lichty B, et al.
J Immunol
. 2007 Feb;
178(4):2387-95.
PMID: 17277145
Genetic immunization holds great promise for future vaccination against mucosal infectious diseases. However, parenteral genetic immunization is ineffective in control of mucosal intracellular infections, and the underlying mechanisms have remained...
12.
Zhang X, Divangahi M, Ngai P, Santosuosso M, Millar J, Zganiacz A, et al.
Vaccine
. 2006 Oct;
25(7):1342-52.
PMID: 17052817
Plasmid DNA vaccine has been widely explored for tuberculosis immunization but there is a need to develop the ways to improve its immunogenicity. In this study, we have constructed a...
13.
Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z
Infect Immun
. 2006 Jul;
74(8):4634-43.
PMID: 16861651
Parenterally administered Mycobacterium bovis BCG vaccine confers only limited immune protection from pulmonary tuberculosis in humans. There is a need for developing effective boosting vaccination strategies. We examined a heterologous...
14.
Malowany J, McCormick S, Santosuosso M, Zhang X, Aoki N, Ngai P, et al.
Mol Ther
. 2005 Dec;
13(4):766-75.
PMID: 16343993
Genetically modified dendritic cell (DC)-based vaccines have not been explored for immunization against tuberculosis. A gene-modified DC vaccine expressing Mycobacterium tuberculosis (M.tb) antigen 85A (Ag85A) was developed by using a...
15.
Xing Z, Santosuosso M, McCormick S, Yang T, Millar J, Hitt M, et al.
Curr Gene Ther
. 2005 Oct;
5(5):485-92.
PMID: 16250889
Tuberculosis vaccine research began with the search for a vaccine that might be better than, and thus could replace, the current Bacillus Calmette Guérin (BCG) vaccine. Over the last fifteen...
16.
Santosuosso M, McCormick S, Xing Z
Viral Immunol
. 2005 Jul;
18(2):283-91.
PMID: 16035940
Adenoviral vector has been extensively studied as a vaccine platform because of its ability to induce potent cellular and humoral immunity. One main advantage of adenoviral vectors is their natural...
17.
Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M, Xing Z
J Immunol
. 2005 Jun;
174(12):7986-94.
PMID: 15944305
The mechanisms underlying better immune protection by mucosal vaccination have remained poorly understood. In our current study we have investigated the mechanisms by which respiratory virus-mediated mucosal vaccination provides remarkably...
18.
Wang J, Thorson L, Stokes R, Santosuosso M, Huygen K, Zganiacz A, et al.
J Immunol
. 2004 Nov;
173(10):6357-65.
PMID: 15528375
Bacillus Calmette-Guerin (BCG) vaccine has failed to control the global tuberculosis (TB) epidemic, and there is a lack of safe and effective mucosal vaccines capable of potent protection against pulmonary...
19.
Wang J, Santosuosso M, Ngai P, Zganiacz A, Xing Z
J Immunol
. 2004 Sep;
173(7):4590-7.
PMID: 15383593
We have investigated whether both primary CD8 T cell activation and CD8 T cell-mediated protection from Mycobacterium tuberculosis challenge could occur in mycobacterial-vaccinated CD4 T cell-deficient (CD4KO) mice. Different from...
20.
Zganiacz A, Santosuosso M, Wang J, Yang T, Chen L, Anzulovic M, et al.
J Clin Invest
. 2004 Feb;
113(3):401-13.
PMID: 14755337
TNF-alpha has long been regarded as a proimmune cytokine involved in antimicrobial type 1 immunity. However, the precise role of TNF-alpha in antimicrobial type 1 immunity remains poorly understood. We...